Research Topics
Genomes and Genes
Species | Irene Y CheungSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastomaIrene Y Cheung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Mol Diagn 9:237-41. 2007..We conclude that CCND1 has potential clinical utility as a novel molecular marker of MRD in the bone marrow of patients with metastatic NB...- Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factorIrene Y Cheung
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
J Clin Oncol 30:426-32. 2012..Although there is ample evidence on how the antibody targets NB, in vivo contribution by GM-CSF remains unclear. This report investigates granulocyte activation and its correlation with treatment outcome... 
Prognostic significance of GAGE detection in bone marrows on survival of patients with metastatic neuroblastomaI Y Cheung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Med Pediatr Oncol 35:632-4. 2000..Among patients with stage III melanoma rendered disease-free by surgery, GAGE expression was a strong prognostic factor for patient survival...- Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastomaIrene Y Cheung
Department of Pediatrics and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 14:7020-7. 2008..Because of tumor heterogeneity, no single marker will likely be adequate. Genome-wide expression profiling can uncover potential MRD markers differentially expressed in tumors over normal marrow/blood... - Novel markers of subclinical disease for Ewing family tumors from gene expression profilingIrene Y Cheung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 13:6978-83. 2007..Genome-wide expression arrays can uncover novel genes differentially expressed in tumors over normal marrow/blood, which may have potentials as markers of subclinical disease... - Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastomaIrene Y Cheung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Int J Cancer 119:152-6. 2006..Similarly, the STX transcript level of posttreatment marrows was also highly prognostic of outcome (PFS, p = 0.001; OS, p < 0.0005). We conclude that STX mRNA has potential clinical utility as a molecular marker of metastatic NB... - Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastomaIrene Y Cheung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 21:3853-8. 2003..To use early marrow response as a prognostic marker is particularly relevant for patients not likely to benefit from this therapy... - Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCRI Y Cheung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center New York, New York 10021, USA
Clin Cancer Res 7:1698-705. 2001..We explore the potential of GD2 synthase mRNA as a molecular marker of minimal residual disease by first comparing it quantitatively with immunocytology and then testing its clinical utility... - Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastomaIrene Y Cheung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 21:1087-93. 2003..Because therapy (myeloablation, immunotherapy, or differentiation) for MRD is applied at the time of clinical remission, objective surrogate markers are needed to gauge treatment efficacy... - Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8Irene Y Cheung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 94:3042-8. 2002..Its utility in bone marrow (BM) purging is evaluated by a real-time reverse transcription-polymerase chain reaction (RT-PCR) assay to quantify the mRNA of GD2 synthase, the key enzyme in GD2 synthesis... - FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factorNai Kong V Cheung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:2885-90. 2006..Granulocyte macrophage colony-stimulating factor (GM-CSF) enhances phagocyte-mediated ADCC. The differential affinity of the human FCGR polymorphic alleles for 3F8 may influence the effectiveness of antibody immunotherapy... - High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapyBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
Pediatr Blood Cancer 48:430-4. 2007..We assessed the impact on rapid HAMA formation of prior chemotherapy in NB patients... - Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapyNai Kong V Cheung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Hybrid Hybridomics 22:209-18. 2003..Anti-idiotypic antibody may provide a useful tool for optimizing gene transduction of CIR fusion constructs into primary human lymphocytes and their continual expansion in vitro... - Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remissionNai Kong V Cheung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Clin Oncol 30:3264-70. 2012..Anti-GD2 monoclonal antibody (MoAb) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) has shown efficacy against neuroblastoma (NB). Prognostic variables that could influence clinical outcome were explored... - Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysisIrene Y Cheung
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York
Cancer 101:2303-8. 2004..03). CONCLUSIONS: BM monitoring should continue to be an integral part of disease follow-up for patients with Stage 4 NB. PB monitoring to complement tumor surveillance in the BM can be informative... - MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumorsHong Xu
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Cancer Res 69:6275-81. 2009..Differential modulation of this key immunoinhibitory molecule in tumor versus normal tissues may advance both cell-mediated immunotherapy and antibody-based targeted strategies using the B7-H3-specific mAb 8H9... - KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastomaJeffrey M Venstrom
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 15:7330-4. 2009..We hypothesized that patients with a "missing ligand" KIR-HLA compound genotype may uniquely benefit from autologous hematopoietic stem cell transplantation (HSCT)... 
Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancerLin Chi Chen
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Ave, New York, NY, United States
Lung Cancer 67:216-20. 2010..We conducted this study to determine if GD2/GM2 synthase RNA could be detected in SCLC cell lines and human tissues, and whether mRNA transcript levels corresponded with disease status...- Association of age at diagnosis and genetic mutations in patients with neuroblastomaNai Kong V Cheung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
JAMA 307:1062-71. 2012..Neuroblastoma is diagnosed over a wide age range from birth through young adulthood, and older age at diagnosis is associated with a decline in survivability... - Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastomaShakeel Modak
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Pediatr Blood Cancer 58:469-71. 2012..Hematopoietic reconstitution was achieved in all three patients receiving plerixafor-primed stem cells after myeloablative therapy. Plerixafor is an effective and safe agent for stem cell collection in patients with NB... - Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastomaHong Xu
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Int J Cancer 129:1953-62. 2011..These results suggest a therapeutic potential of combination therapy using checkpoint kinase inhibitor and chemotherapy to reverse or prevent drug resistance in treating neuroblastomas with defective G(1) checkpoints... - MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomasRuimin Huang
Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
FASEB J 25:4138-49. 2011.... - Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteinsNai Kong V Cheung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Hybrid Hybridomics 21:433-43. 2002..The reduced size resulted in a shorter half-life in vivo, while achieving comparable tumor to nontumor ratio as the native antibody 8H9. However, its in vitro activity in antibody-dependent cell-mediated cytotoxicity was modest... - Detecting minimal residual disease in neuroblastoma patients-the present state of the artKlaus Beiske
Department of Pathology, Rikshospitalet, Sognsvannsveien 23, N 0027 Oslo, Norway
Cancer Lett 228:229-40. 2005....
Research Grants
- Molecular Detection of Occult NeuroblastomaIrene Cheung; Fiscal Year: 2004..If these two molecular markers of MRD can independently predict patient outcome, they will in the future provide an objective endpoint for stopping further treatment, and serve as sensitive surrogates for evaluating adjuvant therapies. ..